{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Epigenetics"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001006015"],"host":["EGA"],"description":["EGA study EGAS00001006015"],"dataset_title":["TAVAREC Methylation"],"repository":["EGA"],"category":["restricted"],"name_synonyms":["clinical trial, clinical_trial, Trial, Clinical Trial, EORTC, DNA methylation maintenance, Unspecified, Clinical Trials, Clinical Trials., DNA, DNA Methylations, DNA methylation, Methylations, Methylation, European Organization for Research and Treatment of Cancer"],"description_synonyms":["Glioma 1, clinical_trial, Trial is Randomized, GLM, glial tumors, Clinical Trials, Significant, randomization, Mixed Glioma, DNA Methylations, tumour of the neuroglia, Tumor, PHASE II TRIAL, Trial, copy_number, Clinical Trial, [M]Glioma NOS (morphologic abnormality), Statistical Significance, tumor of the neuroglia, 2, Methazolastone, Inhibitors, 3, [M]Gliomas (morphologic abnormality), Phase 2 Study, Trial Phase 2, Relapses, Effect, Angiogenesis Factor Inhibitor, randomized, treatment, Copy Number Reported, DNA methylation maintenance, CCRG81045, glioma (morphologic abnormality), Genomes, statistically significant, Recurrences, neuroglial tumour, Neoplasm of the Neuroglia, M&B39831, DNA methylation, Anti-Angiogenetic Agents, Angiogenic Inhibitors, Anti Angiogenesis Effect, Antiangiogenesis Effects, disease management, tumour of neuroglia, Therapies, COPYNUM, Phase II Trial, Gliomas (morphologic abnormality), Positive, glioma, Mvasi, Anti-Angiogenesis Effect, Antiangiogenic Agent, neoplasm of the neuroglia, Angiogenetic Antagonist, Tumors, Add, 1-d)-1, Therapy, Relapse, Glioma (except Nasal glioma, wide/broad, TMZA-HE, Benefits, Angiogenesis, Phase II Study, obsolete_glioma, 1p/19q co-deletion, Clinical Trials., Anti-Angiogenesis Effects, Malignant Glioma, grade 2, Neovascularization, M&B-39831, copy number, Antiangiogenic, Significance, 5-tetrazin-4(3H)-one, clinical trial, Evaluation, Temodal, Evaluated, Recrudescence, significant, Avastin, Antiangiogenesis Effect, Gliomas, Glial Cell Tumor, 1p/19q Codeletion, statistical significance, Antagonists, G2, Prognostic, NSC 362856, NSC-362856, Tumor of Neuroglia, whole genome, Angiogenetic Antagonists, Temodar, Treatments, Neovascularization Inhibitor, Anti Angiogenetic Agent, wide, Anti Angiogenic Drug, Agents, Patient, label, Tumor of the Neuroglia, Phase II Protocol, glial tumour, not neoplastic), Angiogenesis Factor, CCRG-81045, Glioma, Angiostatic Agent, glial neoplasm, DNA, Anti-Angiogenic Drugs, malignant (morphologic abnormality), Inhibitor, Neoplasms of Neuroglia, Methylation, Glioma NOS, Angiogenetic Inhibitor, Angiogenesis Factor Inhibitors, RANDOMIZED, Effects, Phase II Clinical Trial, neuroglial tumor, Temozolomide Hexyl Ester, Neuroglial Tumor, TMZ-Bioshuttle, broad, Malignant, Angiostatic Agents, Angiogenetic Inhibitors, Angiogenetic, Agent, Evaluation Procedure, intermediate grade, CCRG 81045, Randomized, Subject is Randomized, Antiangiogenesis, TMZ Bioshuttle, Mixed Gliomas, Factor Inhibitor, Drugs, Glioma NOS (morphologic abnormality), Recrudescences, Anti-Angiogenetic Agent, Angiogenic, Glial Neoplasm, Antagonist, Angiogenesis Inhibitor, grade II, neuroglial neoplasm, RANDOM, glial tumor, Anti Angiogenetic Agents, Unspecified, Clients, Statistically Significant, Anti-Angiogenetic, Angiogenic Antagonist, phase 2, [M]Gliomas, Tumors of Neuroglia, Methylations, Benefit, malignant, Factor Inhibitors, Antiangiogenic Agents, M&B 39831, Bevacizumab awwb, Loss of Chromosomes 1p/19q, Client, neoplasm of neuroglia, 8-Carbamoyl-3-methylimidazo(5, Addition, Anti-Angiogenesis, del(1p/19q), Anti Angiogenic Drugs, moderately differentiated, Mixed, [M]Glioma NOS, Glial Tumor, Copy Number, NOS (except Nasal glioma, Evaluate, Neuroglial Neoplasm, Neuroglial Neoplasms, Anti-Angiogenic Drug, Neovascularization Inhibitors, Glial Cell, Malignant glioma, Randomization, Angiogenic Inhibitor, NSC362856, Bevacizumab-awwb, Drug, tumor of neuroglia, Neoplasm of Neuroglia, LAB_SEQ_METHOD, no ICD-O subtype, Therapeutic, Phase II, Angiostatic, Angiogenic Antagonists, Glial Cell Tumors, 1p/19q Co-deletion, Malignant Gliomas, Treatment, Anti Angiogenesis Effects, phase II trial, Anti-Angiogenic"],"additional_accession":[]},"is_claimable":false,"name":"DNA methylation profiles of samples included in the EORTC 26091 TAVAREC trial","description":"The TAVAREC trial was a randomized, open-label phase 2 trial assessing the benefit of the addition of the angiogenesis inhibitor bevacizumab to treatment with temozolomide in patients with a first enhancing recurrence of WHO grade 2 or 3 glioma without 1p/19q codeletion. We evaluated the prognostic significance of genome wide DNA methylation profiles and copy number variations on the TAVAREC trial samples.","dates":{"updated":"2022-03-03 14:19:12"},"accession":"EGAS00001006015","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00010002289","EGAC00001002201"]}}